Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733030 · ClinicalTrials.gov registry record
The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 56
- Enrollment target
NCT01733030 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 56 participants.
The verdict
NCT01733030 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
Study Summary
PROJECT SUMMARY: PTSD is a debilitating psychiatric condition precipitated by exposure to extreme, or life threatening, trauma with an estimated lifetime prevalence between 8% and 9% in U.S. adults. One core symptom of PTSD is intense psychological distress in the presence of stimuli that "resemble" one or more aspects of the trauma experience (DSM-IV). This phenomenon referred to as stimulus generalization has received surprisingly little empirical testing in the context of clinical anxiety in general, and PTSD more specifically. The current proposal represents the first effort to study the neurobiology and pharmacology of this PTSD-relevant learning phenomenon across those with and without PTSD. The objective of this particular proposal is to apply fMRI and pharmacologic methods to: 1) identify brain mechanisms associated with generalization of conditioned fear and 2) examine the pharmacologic modifiability of levels of generalization using a partial agonist at the NMDA receptor complex (D-cycloserine) shown to increase discrimination of CS+ (danger cue) and CS- (safety cue) in animal studies.
Interventions
- DRUG Seromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01733030
The ClinicalTrials.gov registry entry for NCT01733030 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Seromycin is the first listed.
NCT01733030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01733030 about?
NCT01733030 is a clinical study titled "The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.". PROJECT SUMMARY: PTSD is a debilitating psychiatric condition precipitated by exposure to extreme, or life threatening, trauma with an estimated lifetime prevalence between 8% and 9% in U.S. adults. One core symptom of PTSD is intense psychological distress in the presence of stimuli that "resemble...
What is the current status of trial NCT01733030?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2013-01. Estimated completion is 2015-10-01.
What interventions are being tested in trial NCT01733030?
The interventions under investigation include: Seromycin (DRUG).
Who is sponsoring clinical trial NCT01733030?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.